Research programme: respiratory tract disorder therapeutics - Chiesi Farmaceutici
Latest Information Update: 27 Dec 2022
At a glance
- Originator Chiesi Farmaceutici
- Class Corticosteroids
- Mechanism of Action Leucocyte elastase inhibitors; P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bronchopulmonary dysplasia
- No development reported Asthma; Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis
Most Recent Events
- 27 Dec 2022 Preclinical development is ongoing in Italy (Chiesi pipeline, December 2022)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Bronchopulmonary-dysplasia in Italy (Inhalation)
- 28 Jun 2018 No recent reports of development identified for preclinical development in Asthma in Italy